Gedeon Richter's First Steps into Biologics
Biogen's choosing Gedeon Richter as its new marketing partner for Avonex in Eastern Europe points to the perceived value of local collaborators-particularly in emerging markets whose regulatory and health care systems differ from those in the West. The deal also takes Richter into Eastern Europe's small, yet potentially high-growth biologics field.
You may also be interested in...
Senexis Ltd. spun-out of the University of Manchester Institute of Science and Technology to develop novel therapeutics and diagnostics for currently incurable aging-related disorders such as Alzheimer's disease, Parkinson's disease and type 2 diabetes. In addition to being more prevalent in the older population, these diseases also share a similar underlying etiology; they are all associated with amyloidosis.
Encouraged by successes in the biotech space, public market investors' interest in the device arena has returned in 2004 to support 10 companies' IPOs so far. Windhover's analysis of the valuations achieved indicate that private investors in these companies have, on average, enjoyed larger returns than their biotech counterparts.
Europe's pre-emption rights significantly hamper biotech fundraising. But since they're unlikely to go away, European firms are having to find clever ways around them.